Cargando…
Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666859/ https://www.ncbi.nlm.nih.gov/pubmed/34966537 http://dx.doi.org/10.1136/flgastro-2020-101760 |
| _version_ | 1784614283814895616 |
|---|---|
| author | McGoran, John Wilson, Alan McErlain, Shannan Kennedy, Noreen Masterson, Caroline Collins, Caroline Morrison, Graham |
| author_facet | McGoran, John Wilson, Alan McErlain, Shannan Kennedy, Noreen Masterson, Caroline Collins, Caroline Morrison, Graham |
| author_sort | McGoran, John |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8666859 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86668592021-12-28 Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic McGoran, John Wilson, Alan McErlain, Shannan Kennedy, Noreen Masterson, Caroline Collins, Caroline Morrison, Graham Frontline Gastroenterol Letter BMJ Publishing Group 2021-05-27 /pmc/articles/PMC8666859/ /pubmed/34966537 http://dx.doi.org/10.1136/flgastro-2020-101760 Text en © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. |
| spellingShingle | Letter McGoran, John Wilson, Alan McErlain, Shannan Kennedy, Noreen Masterson, Caroline Collins, Caroline Morrison, Graham Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic |
| title | Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic |
| title_full | Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic |
| title_fullStr | Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic |
| title_full_unstemmed | Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic |
| title_short | Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic |
| title_sort | initiation of subcutaneous infliximab (remsima) therapy for the treatment of inflammatory bowel disease during the covid-19 pandemic |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666859/ https://www.ncbi.nlm.nih.gov/pubmed/34966537 http://dx.doi.org/10.1136/flgastro-2020-101760 |
| work_keys_str_mv | AT mcgoranjohn initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic AT wilsonalan initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic AT mcerlainshannan initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic AT kennedynoreen initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic AT mastersoncaroline initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic AT collinscaroline initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic AT morrisongraham initiationofsubcutaneousinfliximabremsimatherapyforthetreatmentofinflammatoryboweldiseaseduringthecovid19pandemic |